Biosimilar User Fee Program Reflects PDUFA, Includes SPA Path

Washington Drug Letter
The FDA’s proposed biosimilars user fee program mirrors that for drugs under the Prescription Drug User Fee Act (PDUFA), and includes performance goals for special protocol assessments (SPA) that could help ensure a clear path to approval for the generic biologics, the agency said Tuesday.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00